Conference Call to be Held December 19 Summary: Genmab will hold a conference call on December 19, 2007 to give an update on the ofatumumab (HuMax-CD20) development program. Copenhagen, Denmark; December 14, 2007 - Genmab A/S (OMX: GEN) announced today it will give an update on the ofatumumab (HuMax-CD20(R)) development program during a conference call on December 19, 2007 at 2:00PM GMT/3:00PM CET/9:00AM EST. Genmab's CEO Lisa N. Drakeman, Ph.D., will be joined on the call by Dr. Moncef Slaoui, Chairman, Research & Development at GlaxoSmithKline (GSK). Ofatumumab is an investigational drug being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, rheumatoid arthritis and diffuse large B-cell lymphoma under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any market. Conference Call The conference call will be held on Wednesday, December 19, 2007 at: 3:00PM CET 2:00PM GMT 9:00AM EST The dial in numbers are as follows: +1 800 334 0872 (in the US) +1 913 312 1277 (outside the US) The conference call will be held in English. A live webcast of the call will be available at www.genmab.com. The webcast will also be archived on Genmab's website. About Genmab A/S Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com. This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); and UniBody(R) are all trademarks of Genmab A/S. Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: +45 25 27 47 13, E: hth@genmab.com Investor News No. 17/2007 ###